Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.
Semaglutide isn’t just making waves in metabolic research—it’s now showing promise in reproductive science. A new multicenter cohort study out of Taiwan looked at semaglutide pretreatment in women with overweight and obesity dealing with infertility. Researchers pulled real-world data from multiple clinics and analyzed reproductive outcomes after semaglutide use.
Reprod Biol Endocrinol
by Wu YC, Hsu JC, Su EC et al.
“Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study. Wu YC(1)(2), Hsu JC(3)(4)(5)(6), Su EC(2)(3)(7), Chen CH(1)(8), Chang TH(9)(10). Author information: (1)Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan. (2)Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan. (3)Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan. (4)International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan. (5)Research Center of Data Science on Health Care Industry, College of Management, Taipei Medical University, Taipei, Taiwan. (6)Clinical Data Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan. (7)Institute of Biomedical informatics, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. (8)Department of Obstetrics and Gynecology, College of Medicine, Taipei Medical University, Taipei, Taiwan. (9)Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan. kevinchang@tmu.edu.tw. (10)Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan. kevinchang@tmu.edu.tw. Conflict of interest statement: Declarations. Ethics approval and consent to participate: This study utilized de-identified real-world data from the TriNetX research network. As the dataset contains no directly identifiable patient information and complies with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule, this study did not constitute human subjects research and therefore did not require Institutional Review Board approval or informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.”
Key takeaway: Women who received semaglutide before fertility treatments saw measurable improvements in reproductive outcomes compared to those who didn’t. The study focused on real-world, de-identified data, so these results reflect what’s happening in actual clinics, not just controlled lab settings.
Why does this matter? Obesity can make infertility tougher to treat. Anything that moves the needle on reproductive success is headline-worthy for researchers and clinicians. Semaglutide, already well-known for its effects on weight and metabolic markers, might offer a double win—better metabolic health and improved fertility potential.
What researchers found:
Semaglutide pretreatment was linked with higher pregnancy rates in this cohort
The study used a broad, multicenter dataset, boosting confidence in the findings
Outcomes were measured in a way that reflects everyday clinical reality
The details are still being worked out, but this research adds another chapter to the semaglutide story. The peptide’s impact clearly goes beyond glucose and body weight. For anyone exploring peptide research or sourcing compounds for fertility studies, this is a strong signal to keep an eye on semaglutide’s versatility.
Looking for suppliers or additional research tools? Check the vendor directory for sourcing options. Semaglutide research keeps delivering surprises—expect more updates as the data rolls in.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.